ArticleCardiovascular and interventional radiology2019
Outcomes After Transarterial Embolization of Neuroendocrine Tumor Liver Metastases Using Spherical Particles of Different Sizes.
Article in Cardiovascular and interventional radiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Management of liver metastases from non-functional gastroenteropancreatic neuroendocrine tumors: a systematic review.Frontiers in endocrinology · 2025Pooled it
- Transarterial embolization combined with octreotide long-acting release in treating rectal neuroendocrine tumor liver metastases: a single-institutional experience.Journal of gastrointestinal oncology · 2026Article
- A real-world retrospective analysis to evaluate the efficacy and safety of surufatinib in the treatment of advanced neuroendocrine neoplasms in China.Endocrine connections · 2025Article
- Computed tomography-guided percutaneous biopsy for assessing tumor heterogeneity in neuroendocrine tumor metastases to the liver.World journal of radiology · 2025Article
- Imaging for Interventional Radiology Liver-Directed Therapies for Neuroendocrine Liver Metastases.Seminars in interventional radiology · 2024Review
- Assessing the effectiveness and safety of surufatinib versus everolimus or sunitinib in advanced neuroendocrine neoplasms: insights from a real-world, retrospective cohort study using propensity score and inverse probability treatment weighting analysis.Journal of gastrointestinal oncology · 2024Article
- Predictors of Long-Term Outcomes After Liver Transplantation for Unresectable Metastatic Neuroendocrine Tumors.Annals of transplantation · 2023Article
- Article
- Prolonged progression-free survival achieved by octreotide LAR plus transarterial embolization in low-to-intermediate grade neuroendocrine tumor liver metastases with high hepatic tumor burden.Cancer medicine · 2022Article
- Review
- Small Particle DEBIRI TACE as Salvage Therapy in Patients with Liver Dominant Colorectal Cancer Metastasis: Retrospective Analysis of Safety and Outcomes.Current oncology (Toronto, Ont.) · 2022Article
- Effect of bead size and doxorubicin loading on tumor cellular injury after transarterial embolization and chemoembolization in a rat model of hepatocellular carcinoma.Nanomedicine : nanotechnology, biology, and medicine · 2022Article
- Liver-Directed Therapies for Neuroendocrine Neoplasms.Current oncology reports · 2021Review
- The Role of Interventional Radiology for the Treatment of Hepatic Metastases from Neuroendocrine Tumor: An Updated Review.Journal of clinical medicine · 2020Review
- Embolotherapy for Hepatic Oncology: Current Perspectives and Future Directions.Digestive disease interventions · 2020Article
- Interventional Liver-Directed Therapy for Neuroendocrine Metastases: Current Status and Future Directions.Current treatment options in oncology · 2020Review
- Management of Gastrointestinal Neuroendocrine Tumors.Clinical medicine insights. Endocrinology and diabetes · 2019Review
Corrections and comments
- Commented on by
Authors and funding
8 authors.
Funding
Abstract
purposeTo evaluate initial response and overall survival of neuroendocrine tumor (NET) liver metastases initially treated with transarterial embolization (TAE) using spherical particles of different sizes.
methodsA single-institution retrospective review was performed of 160 patients with NET liver metastases initially treated with TAE using < 100 µm (n = 77) or only ≥ 100 µm (n = 83) spherical particles. For each patient, we evaluated: initial response by mRECIST, time to progression, overall survival, complications, primary site, tumor grade and degree of differentiation, volume of liver disease, extrahepatic disease, NET-related symptoms, comorbidities, Child-Pugh score, performance status, lobar versus selective embolization, and arteriovenous shunting.
resultsInitial response was higher for TAE using particles < 100 versus TAE using only particles ≥ 100 μm (64 vs 42%, p = 0.007). Multivariate logistic regression showed that use of particles < 100 μm and liver < 50% replaced with tumor were independent predictors of a better initial response rate. There was no difference in major or minor complications between the two particle size groups. Median overall survival after TAE was 55 months for well- to moderately differentiated NET and 13 months for poorly differentiated or undifferentiated NET. There was no significant difference in survival between TAE patients treated with < 100 versus only ≥ 100-μm particles.
conclusionNET patients treated with TAE using particles < 100 μm had better initial response, but the same overall survival, compared to TAE using only particles ≥ 100 μm.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.